[
  {
    "question": "Young male patient with isolated optic neuritis, and he is concern that he may has multiple sclerosis. What is the most appropriate next step investigation?",
    "option_a": "Visual evoked potential",
    "option_b": "Brain MRI",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis is an inflammatory demyelinating event of the optic nerve that can be an initial presentation of multiple sclerosis (MS). In a young patient, evaluating for additional CNS lesions is key to assessing the risk for MS. Brain MRI is the recommended test because it can reveal white matter lesions in characteristic locations, fulfilling the dissemination in space requirement of the McDonald criteria. The underlying mechanism in optic neuritis involves immune-mediated demyelination of the optic nerve. In MS, similar demyelinating lesions are scattered throughout the brain, particularly in periventricular, juxtacortical, and infratentorial areas. Brain MRI detects these T2 hyperintense lesions and is crucial in establishing the disease pattern seen in MS, as defined by recent diagnostic guidelines. Patients typically present with painful vision loss and may experience diminished color vision and visual field deficits. The detection of additional demyelinating lesions on brain MRI increases the likelihood that an episode of optic neuritis is associated with MS. This investigation helps stratify patients according to their risk of converting to clinically definite MS. The differential diagnosis includes ischemic optic neuropathy, infectious or inflammatory causes of optic neuritis, and compressive optic neuropathies. Brain MRI helps differentiate MS by revealing other subclinical lesions. Visual evoked potentials (VEP) are useful to determine conduction delay along the optic nerve but do not detect lesions in other parts of the CNS. Initial evaluation with brain MRI guides not only diagnosis but also future management. If MRI findings suggest MS, early initiation of disease-modifying therapies (DMTs) is recommended. First-line treatments include interferon-beta and glatiramer acetate among others. In pregnant or lactating patients, careful selection of DMTs is crucial; interferon-beta has relatively favorable data in pregnancy, whereas MRI contrast agents (like gadolinium) are used with caution. Option A (Visual evoked potential) is supportive to confirm optic nerve conduction delay but does not assess for dissemination in space. Option B (Brain MRI) is the appropriate next investigation as it evaluates the brain for additional demyelinating lesions, aligning with current diagnostic criteria. Options C and D were not provided. 1. Brain MRI is essential in patients with isolated optic neuritis when evaluating for MS. 2. The McDonald criteria incorporate MRI findings to demonstrate dissemination in space and time, which is critical in the early diagnosis of MS. Updated guidelines now emphasize early MRI evaluation in suspected MS cases. Recent research reinforces brain MRI\u2019s role in demonstrating covert lesions and correlates with the risk of developing clinically definite MS.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient had optic neuritis in the right eye. What is the finding in visual potential test?",
    "option_a": "Right eye decrease in P100.",
    "option_b": "Right eye prolonged in P100.",
    "option_c": "Left eye prolonged in P100.",
    "option_d": "Left eye decrease in P100.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Visual evoked potentials (VEP) measure the electrical response of the brain to visual stimuli, evaluating the integrity and speed of the visual pathway. In optic neuritis, demyelination results in a delay in signal conduction, which is reflected as a prolonged P100 latency. Demyelination of the optic nerve slows the conduction of electrical impulses. The P100 wave, which represents the primary cortical response to visual stimuli, is delayed because of disrupted myelin sheaths. This hallmark finding helps to corroborate the clinical diagnosis of optic neuritis. Patients suffering from optic neuritis typically exhibit visual disturbances such as blurry or diminished vision and pain on eye movement. The VEP in the affected (right) eye commonly shows a prolonged P100 latency, confirming the slowed conduction due to demyelination. Although the VEP test is not the sole diagnostic tool, it supports clinical findings. Differential diagnoses could include retinal or optic nerve disorders. However, in demyelinating optic neuritis, the key abnormality is a delayed P100 latency in the affected eye relative to the unaffected eye. Acute management of optic neuritis may involve high-dose intravenous corticosteroids to hasten recovery, though visual outcomes are typically similar with or without treatment. In pregnant patients, steroids such as IV methylprednisolone may be used with caution after weighing risks and benefits. Long-term, assessing the risk for MS is important, and additional workup (like MRI) may be warranted. Option A (Right eye decrease in P100) suggests a reduction in amplitude rather than a delay, which is less specific. Option B (Right eye prolonged in P100) correctly describes the classic finding in demyelinating optic neuritis. Options C and D target the left eye, which is not relevant in isolated right eye involvement. 1. The hallmark VEP abnormality in optic neuritis is a prolonged P100 latency in the affected eye. 2. VEP abnormalities can persist even after clinical recovery and are useful in documenting the demyelinating process. Current research supports the use of VEP as a sensitive measure of optic nerve conduction abnormalities in demyelinating diseases. Recent updates suggest that combining electrophysiological data with imaging enhances diagnostic accuracy for MS.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young female with previous history of two optic neuritis attacks, came with new symptoms of spinal cord lesions, MRI attached showed extensive hyperintense T2 lesions from C8-T0 ( no documented reported ), Aquaporin 4 is negative. What is the most likely diagnosis?",
    "option_a": "Relapsing remitting multiple sclerosis",
    "option_b": "Neuromyelitis optica spectrum disorder",
    "option_c": "Acute disseminated encephalomyelitis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "A young female with a history of recurrent optic neuritis presenting with a new spinal cord syndrome raises the concern for neuromyelitis optica spectrum disorder (NMOSD). A key component of NMOSD is the occurrence of longitudinally extensive transverse myelitis (LETM), defined as lesions spanning three or more vertebral segments. NMOSD is characterized by immune-mediated damage to the central nervous system, particularly targeting astrocytes through antibodies against aquaporin-4 (AQP4). However, approximately 20-30% of clinically typical NMOSD cases can be AQP4-antibody negative, and these patients may still fit the NMOSD spectrum based on clinical and radiological findings. Recurrent episodes of optic neuritis coupled with a LETM pattern in the spinal cord (here from C8-T0) strongly favors NMOSD over relapsing-remitting MS, which typically exhibits shorter spinal cord lesions. AQP4 negativity does not exclude the diagnosis if clinical findings are striking. The differential diagnosis includes relapsing-remitting MS, which usually shows smaller, patchy lesions in the spinal cord, and acute disseminated encephalomyelitis (ADEM), which is typically a monophasic illness and more common in pediatric populations. Testing for both AQP4 and myelin oligodendrocyte glycoprotein (MOG) antibodies can further delineate the diagnosis. Acute NMOSD relapses are managed with high-dose intravenous corticosteroids, and if the response is inadequate, plasma exchange may be indicated. Long-term immunosuppressive therapy (e.g., rituximab, mycophenolate mofetil) is recommended for preventing relapses. In pregnancy, the use of corticosteroids is generally acceptable, while long-term immunosuppressants should be chosen carefully after evaluating potential fetal risks. Option A (Relapsing remitting multiple sclerosis) is less likely because MS typically presents with shorter spinal lesions and a different lesion distribution. Option B (Neuromyelitis optica spectrum disorder) is the best fit given the clinical history and radiological findings, even with a negative AQP4 result. Option C (Acute disseminated encephalomyelitis) is usually monophasic and does not match the recurrent nature of this patient\u2019s episodes. 1. Longitudinally extensive transverse myelitis (LETM) is a red flag for NMOSD. 2. A history of recurrent optic neuritis further strengthens the consideration of NMOSD, regardless of AQP4 serostatus. Recent guidelines and research highlight the importance of early and aggressive immunosuppressive treatment in NMOSD to prevent irreversible neurological damage. There is ongoing research into additional biomarkers such as anti-MOG antibodies for patients who are AQP4-negative.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "MS on finglmoid , image showed new activity, next.",
    "option_a": "Natalizumab",
    "option_b": "Glatemare Acetate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In patients with MS, breakthrough disease activity\u2014evidenced by new lesions on imaging despite ongoing disease-modifying therapy (DMT)\u2014indicates that the current therapy may be suboptimal. This scenario often calls for an escalation in treatment efficacy. MS is driven by an immune-mediated attack on the myelin sheaths of CNS neurons. Fingolimod works by sequestering lymphocytes in lymph nodes but may not completely suppress disease activity in all patients. The appearance of new lesions on MRI suggests ongoing inflammatory processes despite treatment. A patient on fingolimod with new MRI activity is experiencing subclinical disease activity, which may eventually lead to clinical relapses and accumulating disability. This change necessitates a review and probable escalation of therapy. Before escalating therapy, it is important to verify medication adherence, rule out other causes for the new lesions (such as infections or technical MRI variations), and review disease history. Alternatives like glatiramer acetate are generally considered less potent and are unlikely to control breakthrough disease effectively. For patients with breakthrough disease on fingolimod, the current guidelines suggest escalating to a more potent DMT. Natalizumab is a high-efficacy option that has demonstrated robust results in controlling disease activity. In the context of pregnancy or lactation, both fingolimod and natalizumab have limitations; natalizumab is generally used with caution and requires careful counseling regarding its risk-benefit profile if a patient is or becomes pregnant. Option A (Natalizumab) is the appropriate choice for escalating treatment in the face of breakthrough disease activity, given its higher potency relative to glatiramer acetate. Option B (Glatiramer acetate) is a less potent therapy and not ideal for patients already failing fingolimod. Options C and D were not provided. 1. New MRI lesions in a patient on fingolimod indicate potential treatment failure and may necessitate a switch to a more potent DMT. 2. Natalizumab is highly effective in controlling disease activity but requires monitoring for risks such as PML. Recent studies and guidelines support early treatment escalation in patients with breakthrough MS activity. Natalizumab remains a well-established option for highly active relapsing MS, with ongoing research focusing on balancing efficacy with safety, especially in women of childbearing age.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS on Natalaziumab, developed PML, management",
    "option_a": "Stop Natalizumab",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a monoclonal antibody used in the treatment of multiple sclerosis (MS) that works by blocking alpha-4 integrin, thereby preventing lymphocyte migration across the blood\u2010brain barrier. This mechanism, while useful in reducing MS inflammatory activity, unfortunately predisposes patients to opportunistic infections like progressive multifocal leukoencephalopathy (PML). By inhibiting immune cell trafficking into the central nervous system, natalizumab reduces immune surveillance. In patients who are JC virus (JCV) seropositive, this lack of surveillance can allow latent JCV to reactivate. The virus then infects oligodendrocytes causing demyelination, which is the hallmark of PML. Risk increases with duration of therapy and previous immunosuppressive treatments. PML typically presents with progressive neurological deficits such as motor weakness, cognitive impairment, visual disturbances, and ataxia. MRI findings often reveal multifocal, non-enhancing white matter lesions, and cerebrospinal fluid (CSF) analysis using polymerase chain reaction (PCR) for JCV DNA is utilized to confirm the diagnosis. Diagnostic workup includes brain MRI for characteristic white matter lesions and CSF PCR for JCV. Differential diagnoses include an MS relapse, CNS lymphoma, and other infectious or inflammatory conditions, which are distinguished by imaging features, clinical course, and CSF findings. The first-line management involves immediate discontinuation of natalizumab. In selected cases, plasma exchange (PLEX) may be used to accelerate drug clearance. Management also includes supportive care and careful monitoring for immune reconstitution inflammatory syndrome (IRIS). In pregnant or lactating patients, treatment must balance the risks; emerging guidelines advise discontinuing natalizumab in the setting of PML to minimize further neurological damage while considering both maternal and fetal safety. Option A, 'Stop Natalizumab,' is the correct initial therapeutic step in the management of natalizumab-associated PML. The other options are not provided, but the critical action is to stop the drug immediately to prevent further immune suppression. 1) Always screen for JC virus seropositivity before initiating natalizumab. 2) Maintain vigilance for early signs of PML in patients on natalizumab. 3) Early drug discontinuation is crucial to mitigate disease progression. Recent studies and updated guidelines emphasize regular JC virus antibody monitoring and neuroimaging for patients receiving natalizumab. Emerging evidence also supports the use of plasma exchange to accelerate drug removal, though management should be individualised based on patient risk factors.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS patient on DMT, lost follow up, came to ER low plt, pic show (skin rash).",
    "option_a": "Ofatumumab",
    "option_b": "Alemtuzumab",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Alemtuzumab is a monoclonal antibody targeting CD52, utilized in the treatment of MS due to its potent immunomodulatory properties. However, it is also notorious for inducing secondary autoimmune disorders, including immune thrombocytopenia (ITP), which can manifest clinically with skin rashes. Alemtuzumab causes profound lymphocyte depletion followed by immune reconstitution. This reconstitution can be dysregulated, leading to the development of autoimmune conditions. Autoimmune thrombocytopenia results from the generation of autoantibodies targeting platelets. Patients developing ITP may present with a markedly low platelet count and corresponding skin findings such as petechiae or purpura. In this case, the patient exhibited a skin rash and thrombocytopenia, which is a recognized complication of alemtuzumab therapy. The diagnosis involves confirming thrombocytopenia with a complete blood count, evaluating peripheral smear findings, and excluding other causes such as drug-induced thrombocytopenia from other agents or primary hematologic disorders. Differential diagnoses include ITP secondary to other medications or idiopathic causes. Management includes ceasing further doses of alemtuzumab if significant autoimmune sequelae arise. Treatment of ITP may involve corticosteroids, intravenous immunoglobulin (IVIG), or other immunosuppressive therapies depending on severity. For pregnant or lactating patients, the risks and benefits must be carefully weighed since data is limited; alternative treatments may be preferred to avoid autoimmune complications that can adversely affect fetal development. Option B, 'Alemtuzumab,' is correct due to its well-documented association with autoimmune phenomena like immune thrombocytopenia. Option A (Ofatumumab) does not typically present with such hematological adverse effects and thus is less likely to be the culprit. 1) Patients on alemtuzumab require long-term monitoring for secondary autoimmune disorders. 2) Early recognition and management of ITP are critical for preventing severe bleeding complications. 3) Autoimmune manifestations can emerge months to years after therapy. Recent guidelines recommend monthly blood counts for at least 48 months post-alemtuzumab administration to monitor for autoimmune cytopenias. Emerging evidence supports the need for stringent follow-up protocols to detect and treat these complications early.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Most common to be associated with MS",
    "option_a": "HSV",
    "option_b": "EBV",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Epstein-Barr virus (EBV) is a ubiquitous herpesvirus with a strong epidemiological association with multiple sclerosis (MS). Nearly all MS patients have serological evidence of previous EBV infection, suggesting a contributory role in disease pathogenesis. The leading hypothesis involves molecular mimicry, where the immune response to EBV shares similarities with myelin antigens, thereby triggering an autoimmune attack on the central nervous system. B-cell dysregulation induced by EBV infection may further precipitate the autoimmune cascade seen in MS. Primary EBV infection often presents as infectious mononucleosis, especially in adolescents and young adults. In MS, the near-universal seropositivity for EBV supports the theory that an aberrant immune response to the virus may predispose individuals to developing MS. While EBV serology (including anti-VCA and anti-EBNA antibodies) confirms prior infection, it is not used to diagnose MS. Differential considerations include other herpesviruses; however, there is a unique and significant association between EBV and MS that is not shared with, for example, herpes simplex virus (HSV). There is no specific antiviral treatment for EBV in the context of MS. However, understanding the link helps in risk stratification and reinforces the need for research into EBV-targeting strategies. In pregnant or lactating women, management remains supportive as there is no evidence-based indication for antiviral therapy against EBV in this setting. Option B, 'EBV,' is correct because extensive research has established a strong association between EBV seropositivity and the development of MS, whereas HSV does not have a similar correlation. 1) Nearly 100% of MS patients are EBV seropositive, highlighting a unique association. 2) Molecular mimicry is a central concept in the potential pathogenesis of MS related to EBV. 3) The timing of primary EBV infection may influence subsequent MS risk. Recent large-scale cohort studies and systematic reviews continue to support the critical association between EBV and MS. New research is exploring the potential for EBV-specific vaccines or antiviral therapies as preventive strategies in high-risk populations.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS pt on medication resulted in blurry vision, macular edema.",
    "option_a": "Fingolimod",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator used in the treatment of relapsing-remitting MS. Its therapeutic effect is achieved by sequestrating lymphocytes within lymph nodes, thus preventing them from reaching the central nervous system. Fingolimod\u2019s action on S1P receptors also affects ocular tissues. It can increase retinal vascular permeability, which may lead to fluid accumulation in the macula (macular edema). This side effect is dose-related and has been well documented. Patients on fingolimod presenting with blurry vision should be evaluated for macular edema. On ophthalmologic examination, specifically optical coherence tomography (OCT), fluid accumulation in the macula can be visualized, confirming the diagnosis. The diagnostic process involves a detailed ophthalmologic evaluation including a dilated fundus exam and OCT imaging. Differential diagnoses include diabetic macular edema, retinal vein occlusion, and other drug-induced ocular effects, which can be ruled out based on history and ancillary testing. First-line management includes discontinuing fingolimod if significant macular edema is detected. Baseline and periodic ophthalmologic screening is recommended, typically within the first 3-4 months of initiation. For pregnant or lactating patients, fingolimod is generally contraindicated due to teratogenic risks; alternative therapies should be considered to mitigate potential harm. Option A, 'Fingolimod,' is correct as it is the recognized MS disease modifying therapy associated with the development of macular edema. The other options, though not listed here, do not share the same risk profile for this specific adverse event. 1) Regular ophthalmologic monitoring is essential for patients on fingolimod. 2) Blurry vision in a patient taking fingolimod should prompt immediate evaluation for macular edema. 3) Discontinuation of fingolimod often leads to resolution of macular edema. Recent clinical guidelines emphasize the need for baseline eye examinations followed by periodic monitoring for patients initiating fingolimod. Updated research further corroborates the relationship between S1P receptor modulation and retinal vascular permeability changes leading to macular edema.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS lesions pattern of distribution.",
    "option_a": "Oligodendrocytes cell body.",
    "option_b": "Venules.",
    "option_c": "Arterioles.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "MS lesions have a characteristic perivenular distribution. On MRI, this is seen as lesions radiating outward from small veins, classically referred to as 'Dawson\u2019s fingers.' The lesions are not centered on the cell bodies of oligodendrocytes or along arterial territories, but rather around small venules. Multiple sclerosis is an immune-mediated demyelinating disease where autoreactive T-cells cross the blood-brain barrier and attack myelin. The inflammatory process tends to begin around the postcapillary venules, leading to perivenular demyelination. This perivenular pattern is a hallmark of the disease and helps explain the lesion morphology seen on imaging. The perivenular lesions correlate with clinical symptoms of MS such as motor weakness, sensory disturbances, and visual deficits. Radiologically, the distribution of these lesions helps differentiate MS from other white matter disorders, directing the clinician toward the correct diagnosis and treatment approach. The main differentials include neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis, both of which show different lesion patterns and clinical courses. MRI (with T2/FLAIR sequences) along with CSF analysis (for oligoclonal bands) are pivotal in establishing the diagnosis by demonstrating dissemination in space and time. Acute relapses are typically managed with high-dose intravenous corticosteroids. Disease-modifying therapies (DMTs) such as interferon beta, glatiramer acetate, or newer agents (e.g., ocrelizumab) are used for long-term management. In pregnancy and lactation, treatment must be individualized; for example, some DMTs are contraindicated during pregnancy, so alternatives or postponement of treatment may be recommended with close monitoring. Option A (Oligodendrocytes cell body) is incorrect as it misidentifies the target structure. Option B (Venules) is correct since MS lesions primarily form around venules. Option C (Arterioles) is incorrect because the lesions do not follow an arterial distribution. Option D is not provided. 1) 'Dawson\u2019s fingers' on MRI are a classic sign of MS. 2) Recognize that the perivenular inflammation underscores the pathology of MS and aids in diagnosis. Recent research and updated McDonald criteria continue to stress the importance of lesion morphology and distribution in early diagnosis. Advances in high-resolution MRI techniques have improved detection of perivenular lesions, leading to earlier treatment initiation which can positively affect long-term outcomes.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS pt came with Lt eye no abduction or adduction while on Rt eye there is abduction only.",
    "option_a": "BINO",
    "option_b": "INO",
    "option_c": "One and half",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "One-and-a-half syndrome is a distinct brainstem disorder affecting horizontal eye movements. It is characterized by a complete loss of horizontal movement in one eye (both abduction and adduction) and a limitation in the opposite eye, which can only abduct. This syndrome typically results from a lesion in the pontine tegmentum that involves both the paramedian pontine reticular formation (PPRF) and the ipsilateral medial longitudinal fasciculus (MLF). In multiple sclerosis, demyelinating plaques may develop in these areas, leading to the observed ocular motility deficits. In the case described, the left eye shows neither abduction nor adduction while the right eye only abducts. This fits perfectly with one-and-a-half syndrome. It is crucial to differentiate this from a simple internuclear ophthalmoplegia (INO), where only adduction is impaired on the affected side accompanied by abducting nystagmus in the contralateral eye. Differential diagnoses include bilateral internuclear ophthalmoplegia (BINO) and isolated INO. Detailed neuro-ophthalmologic examination combined with brain MRI helps to pinpoint the lesion location in the brainstem. In stroke-related cases, vascular imaging may also be warranted, although in younger MS patients, demyelination is more likely. Treatment focuses on managing the acute demyelinating event with high-dose IV corticosteroids. Long-term, MS disease-modifying therapies (DMTs) are used to reduce relapse frequency. In pregnant or lactating patients, corticosteroids are generally considered safe for short-term use, but the choice of DMT must be carefully considered to avoid teratogenic drugs and ensure maternal-fetal safety. Option A (BINO) is incorrect because bilateral internuclear ophthalmoplegia typically spares ocular abduction in one eye. Option B (INO) is also incorrect because INO affects only adduction. Option C (One and a half syndrome) is correct as it best describes the combination of complete horizontal movement loss in one eye with limited abduction in the other. Option D is not provided. 1) One-and-a-half syndrome is highly localizing for a pontine lesion affecting both the PPRF and the MLF. 2) In MS patients, unusual brainstem presentations like this should prompt thorough imaging to guide management. Advances in neuroimaging have improved the detection and localization of brainstem lesions in MS. Current guidelines recommend early use of high-dose steroids for acute brainstem relapses, with careful selection of long-term DMTs based on the patient\u2019s overall risk profile, including considerations for women of childbearing age.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Pt with MS what is true about MS.",
    "option_a": "Simultaneous bilateral ON would suggest to look for other diagnosis",
    "option_b": "Incomplete recovery is typical with MS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis (ON) is a common initial presentation of MS and is typically unilateral. The occurrence of simultaneous bilateral optic neuritis is unusual in typical multiple sclerosis and should raise suspicion for alternative diagnoses. In MS, demyelination is usually patchy and asymmetric, leading to unilateral involvement of the optic nerve. Bilateral simultaneous ON is more characteristic of disorders such as neuromyelitis optica spectrum disorder (NMOSD), where the immunopathogenesis (often involving anti-aquaporin-4 antibodies) causes a different pattern of tissue injury. A patient with MS usually presents with pain and vision loss in one eye followed by some degree of recovery. In contrast, bilateral optic neuritis, especially when simultaneous, is atypical for MS and warrants evaluation for alternative or overlapping demyelinating diseases. The differential for bilateral ON includes NMOSD, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, and even ischemic optic neuropathies in some cases. Workup generally includes brain and spinal cord MRI along with serologic testing for aquaporin-4 and MOG antibodies to distinguish these conditions from MS. In MS-related optic neuritis, acute treatment is typically with high-dose IV corticosteroids followed by an oral taper. For suspected NMOSD or MOG-associated ON, immunosuppressive therapies (such as rituximab) are indicated instead. In pregnant or lactating patients, careful consideration is given to the safety profiles of these medications, with steroids remaining the first line for acute management. Option A is correct because simultaneous bilateral ON is not characteristic of MS and should lead clinicians to search for other diagnoses such as NMOSD. Option B is incorrect because though recovery in optic neuritis might be incomplete in some cases, a good recovery is more typically seen with MS-related ON, making the statement less accurate. 1) MS-related optic neuritis is usually unilateral; bilateral involvement is a red flag for other demyelinating diseases. 2) Always consider NMOSD in patients with bilateral ON and perform appropriate serum antibody testing. Recent updates in demyelinating disease criteria emphasize the role of serum biomarkers (like AQP4 antibodies) in differentiating MS from NMOSD. Emerging research continues to refine treatment paradigms for acute ON episodes, particularly with respect to early intervention and long-term immunomodulation.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MS pt with ON, MRI showed 1 periventricular lesion",
    "option_a": "CIS",
    "option_b": "RRMS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "A Clinically Isolated Syndrome (CIS) is defined as the first clinical episode of neurologic symptoms lasting at least 24 hours that is caused by inflammation or demyelination in the central nervous system. Optic neuritis accompanied by a solitary periventricular lesion on MRI typically represents CIS rather than a definitive diagnosis of MS. In CIS, demyelinating damage is present but has not met the full criteria for dissemination in space and time needed to diagnose MS. The presence of a single lesion indicates localized inflammation, and while it is concerning for future development into MS, it does not yet fulfill the 2017 McDonald criteria for MS. A patient presenting with optic neuritis and a solitary periventricular lesion fits the picture of CIS. In MS, one would expect multiple lesions or clinical events (relapses) to demonstrate dissemination. This distinction is important for prognosis and therapeutic decision-making. The differential diagnosis includes MS, NMOSD, and other causes of optic neuritis. The key distinction uses the McDonald criteria which require evidence of dissemination in space and time. Serial imaging and clinical follow-up are warranted to monitor for the development of additional lesions. Management of CIS may involve initiating disease-modifying therapies (DMTs) in high-risk patients to delay the conversion to MS. During the acute phase of optic neuritis, high-dose IV corticosteroids are often used. In pregnant or lactating patients, steroid use is acceptable in the short term, but decision-making regarding DMT initiation must consider the safety profile of the drug during pregnancy and lactation. Option A (CIS) is correct because a single clinical episode with only one periventricular lesion does not meet the criteria for RRMS. Option B (RRMS) is incorrect, as relapsing-remitting MS requires dissemination in space and time demonstrated by multiple clinical or radiologic events. 1) CIS represents the first demyelinating event and is a critical window for early intervention. 2) A solitary lesion on MRI in the setting of optic neuritis requires close follow-up, as additional lesions on subsequent imaging are predictive of progression to MS. Current guidelines advocate for a cautious approach in patients with CIS, with some evidence suggesting early initiation of DMTs may delay conversion to MS. Ongoing research continues to refine risk stratification based on initial lesion load, with serial MRI monitoring playing a key role in management decisions.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Lady came with personality change, hearing loss MRI showed. (Similar Pic)",
    "option_a": "Susac",
    "option_b": "MS",
    "option_c": "NMO",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Susac syndrome is a rare autoimmune microangiopathy that affects the brain, retina, and cochlea. It ideally presents with a clinical triad: encephalopathy (which may manifest as personality changes or cognitive impairment), branch retinal artery occlusions, and sensorineural hearing loss. The syndrome is believed to be mediated by an autoimmune process that results in injury to the endothelial cells of small vessels. This endothelial damage causes microvascular occlusions, particularly affecting the corpus callosum in the brain, the retinal arterioles, and the inner ear structures. MRI findings often reveal characteristic 'snowball' lesions in the corpus callosum. In this patient, personality change and hearing loss are significant clues. Although the full triad may not always be present simultaneously, hearing loss paired with neuropsychiatric symptoms should raise suspicion for Susac syndrome over other demyelinating conditions like MS or neuromyelitis optica. The diagnosis is clinical and radiographic. Key steps include: obtaining an MRI (often showing corpus callosum lesions), performing fluorescein retinal angiography to detect branch retinal artery occlusions, and conducting audiometry studies. Important differentials such as multiple sclerosis and NMO are considered but typically lack the complete triad of Susac syndrome. There is no universally accepted treatment, but current guidelines favor early aggressive immunosuppression to limit irreversible damage. First-line treatment typically involves high-dose steroids, often combined with intravenous immunoglobulin (IVIG) or other immunosuppressive agents. In pregnant or lactating patients, the use of steroids is generally acceptable with close monitoring, although other immunosuppressants require careful risk\u2010benefit evaluation. Option A (Susac) is correct because the clinical picture of personality changes and hearing loss with supportive MRI findings is most consistent with Susac syndrome. Option B (MS) is incorrect since multiple sclerosis usually presents with periventricular white matter lesions and lacks the characteristic branch retinal artery occlusions and sensorineural hearing loss. Option C (NMO) primarily affects the optic nerves and spinal cord and does not account for the hearing loss or the specific MRI findings noted. 1. Always consider Susac syndrome in patients presenting with the triad of encephalopathy, branch retinal artery occlusions, and hearing loss, even if all elements are not simultaneously evident. 2. MRI findings, notably lesions in the corpus callosum, are highly suggestive of this syndrome. 3. Early immunosuppressive treatment may prevent long-term sequelae. Recent studies emphasize early recognition and prompt immunosuppressive therapy to minimize permanent neurological and sensory deficits. Research continues to explore targeted biologic therapies that may offer improved outcomes in this rare condition.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Lady known case of MS diagnosis based of hx of one year ago leg numbness, she is on teriflunomide no improvement, she also has eye itchiness, on exam has dental carries especially on gum line.",
    "option_a": "Repeat workup of MS",
    "option_b": "Shimmer test (SJS)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Sjogren's syndrome is an autoimmune disorder primarily affecting exocrine glands such as the lacrimal and salivary glands. This results in decreased secretions, manifesting clinically as dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), which predispose to dental caries. The condition involves lymphocytic infiltration and subsequent destruction of the glandular tissue. This immune-mediated process results in reduced tear and saliva production, leading to ocular irritation and increased dental decay, particularly along the gum line. The patient, originally diagnosed with MS based on leg numbness, is not improving on teriflunomide. The presence of eye itchiness coupled with dental caries along the gum line strongly suggests an alternative diagnosis. These features are classic for Sjogren's syndrome, in which the Schirmer test is used to assess tear production. Diagnosis is based on clinical symptoms supported by objective testing. A Schirmer test is used to measure tear production. Additional tests include serologic markers (anti-Ro/SSA and anti-La/SSB antibodies). Differential diagnoses include MS and other autoimmune conditions; however, the ocular dryness and dental decay lean toward Sjogren's. Management is focused on symptomatic relief. First-line therapy includes artificial tears and saliva substitutes. Systemic agents like hydroxychloroquine may be considered for extraglandular manifestations. In pregnancy and lactation, hydroxychloroquine is generally considered safe, though other immunomodulatory drugs may be contraindicated. Option B (Schirmer test) is the correct choice because it is the key diagnostic assessment for Sjogren's syndrome by evaluating dry eye production. Option A (Repeat workup of MS) would be an inappropriate step given the clinical clues pointing toward a different diagnosis. Options C and D are not provided. 1. Persistent dry eyes and dental caries with gum involvement should prompt evaluation for Sjogren's syndrome rather than a neurological relapse of MS. 2. The Schirmer test is a quick, non-invasive method to assess tear production. 3. Misdiagnosis can occur when neurological symptoms overlap, making it important to assess for systemic signs. Current guidelines recommend a combination of clinical evaluation and serologic tests for early diagnosis of Sjogren's syndrome. Emerging research is focusing on novel biomarkers and targeted therapies to better manage and potentially slow glandular destruction, with an emphasis on safe management during pregnancy and lactation.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "18 yrs old boy came with vertigo, exaggerate dermatology reaction while insert IV, MRI showed.",
    "option_a": "Bahchet",
    "option_b": "Sogren",
    "option_c": "Susac",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Behcet's disease is a multisystem inflammatory vasculitis characterized by recurrent mucocutaneous lesions, including oral and genital ulcers, uveitis, and skin hyperreactivity. A hallmark of the disease is a positive pathergy test, where minor skin trauma (such as an IV insertion) leads to an exaggerated localized inflammatory response. Behcet's involves immune-mediated vasculitis affecting vessels of all sizes. The exact etiology remains unclear, but genetic predisposition (e.g., HLA-B51 association) and environmental triggers contribute to the abnormal immune response. The pathergy phenomenon is thought to result from an altered neutrophilic response to minor trauma. The 18-year-old boy\u2019s presentation with vertigo could be due to brainstem involvement (neuro-Behcet) while the exaggerated skin reaction at the IV site points toward a positive pathergy test. These features collectively support the diagnosis of Behcet's disease rather than a primary neurological disorder. Diagnosis of Behcet's disease is primarily clinical and based on the International Criteria for Behcet's Disease, which includes recurrent oral ulcers, genital ulcers, skin lesions, ocular inflammation, and a positive pathergy test. Differential diagnoses include multiple sclerosis and Susac syndrome, but these conditions do not exhibit the characteristic pathergy reaction. First-line management consists of corticosteroids to control acute inflammation, often combined with immunosuppressive agents such as azathioprine or cyclosporine for more severe or refractory cases. Recently, biologic therapies (like TNF inhibitors) have been used successfully in cases resistant to conventional treatment. In pregnant or lactating patients, corticosteroids can be used with caution, whereas many immunosuppressants and biologics require careful evaluation regarding fetal safety. Option A (Behcet\u2019s disease, albeit labeled as 'Bahchet') is correct given the clinical indicators: neurologic involvement (vertigo) and an exaggerated skin reaction (pathergy). Option B (Sogren) is related to Sjogren's syndrome and does not match the current presentation, while Option C (Susac) is associated with a different triad (encephalopathy, branch retinal artery occlusions, and hearing loss). 1. A positive pathergy test is a key diagnostic clue in Behcet\u2019s disease. 2. Neurological involvement (neuro-Behcet) can manifest as brainstem symptoms like vertigo. 3. Behcet\u2019s disease has a predilection for young patients and displays a wide spectrum of systemic symptoms. Recent research in Behcet's disease emphasizes the role of early immunosuppression to prevent irreversible damage, with ongoing studies evaluating the efficacy of biologic agents in refractory cases. Current guidelines also stress the importance of a multidisciplinary approach, especially in patients with neurological involvement.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly areflexia (tendon reflex un-obtained, ophthalmoplegia, finger to nose test impaired, since 2 days next step, no hx about infection or vaccine. What is Ab.",
    "option_a": "Anti-GQ1b",
    "option_b": "?",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Miller Fisher Syndrome (MFS) is a rare variant of Guillain\u2013Barr\u00e9 syndrome. It is classically defined by a clinical triad: ophthalmoplegia, ataxia, and areflexia. The condition is thought to be immune-mediated, often triggered by an infection, which leads to the production of anti-GQ1b antibodies that attack nerve components, particularly in the cranial nerves. Even in the absence of a clear historical trigger (such as infection or vaccination), the presence of anti-GQ1b antibodies is highly specific for MFS. The elderly patient presents with a sudden onset (over 2 days) of areflexia (tendon reflex un-obtained), ophthalmoplegia, and impaired coordination (finger-to-nose test difficulty). This constellation of findings is typical of MFS, despite the absence of a reported preceding infection or vaccine exposure. The diagnosis of MFS relies on clinical examination supported by serologic testing for anti-GQ1b antibodies. Nerve conduction studies and cerebrospinal fluid analysis (which may show albuminocytologic dissociation) can further support the diagnosis. Key differentials include brainstem stroke and other variants of Guillain\u2013Barr\u00e9 syndrome, which can be differentiated based on clinical findings and specific antibody profiles. The mainstay treatment for MFS is intravenous immunoglobulin (IVIG) or plasmapheresis; these modalities are considered first-line. Corticosteroids are generally not effective. In pregnancy and lactation, IVIG is preferred due to its favorable safety profile. Supportive care, including monitoring of respiratory function, is also important. Option A (Anti-GQ1b) is correct because the detection of anti-GQ1b antibodies is well established in the diagnosis of Miller Fisher Syndrome. The other options, which are not provided or are irrelevant, do not align with the clinical picture. 1. MFS is characterized by the triad of ophthalmoplegia, ataxia, and areflexia. 2. Anti-GQ1b antibody positivity is a key diagnostic marker for MFS. 3. Even without a clear history of preceding infection, MFS should be considered when this clinical triad is present. Recent studies continue to validate the specificity of anti-GQ1b antibodies in MFS, and current treatment guidelines recommend IVIG as first-line therapy. Ongoing research is evaluating the long-term outcomes and the potential role of early intervention in improving recovery rates.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Male known case of testicular cancer came with encephalitis.",
    "option_a": "Ant-Ma2",
    "option_b": "anti-hu",
    "option_c": "anti-LG1",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Paraneoplastic encephalitis is an immune-mediated condition wherein antibodies generated in response to a tumor cross-react with neuronal antigens. In male patients with testicular cancer, Anti-Ma2 antibody is classically associated with paraneoplastic neurological syndromes, particularly those affecting the limbic system. Anti-Ma2 antibodies target neuronal proteins that are aberrantly expressed by the tumor cells. This molecular mimicry results in an inflammatory attack on neuronal tissues, predominantly in the medial temporal lobes, leading to encephalitic features. Evidence suggests that immunological cross-reactivity is central to the development of these syndromes, and early identification may mitigate irreversible neuronal damage. Patients typically present with subacute cognitive decline, memory impairment, behavioral changes, and sometimes seizures. In a patient with known testicular cancer, the development of encephalitic symptoms should immediately raise suspicion for a paraneoplastic process mediated by anti-Ma2 antibodies. Workup includes brain MRI (often showing medial temporal lobe abnormalities), cerebrospinal fluid analysis (which may reveal inflammatory markers or albuminocytologic dissociation), and serum/CSF paraneoplastic antibody panels. Differential diagnoses include infectious encephalitis (such as herpes simplex encephalitis) and other autoimmune encephalitides, which are differentiated by clinical history, imaging, and specific antibody profiles. Management involves a two-pronged approach: treating the underlying malignancy and using immunotherapy to address the autoimmune process. First-line treatment typically includes high-dose corticosteroids, IV immunoglobulin (IVIG), or plasmapheresis. Second-line immunosuppressants (e.g., rituximab) may be considered if initial therapies fail. Although pregnancy and lactation considerations are not applicable for this male patient, similar protocols in female patients emphasize the safety profile of immunotherapy agents during pregnancy while balancing maternal and fetal risks. Option A (Anti-Ma2) is correct because it is the antibody most commonly associated with the paraneoplastic encephalitis seen in testicular cancer. Option B (anti-Hu) is more frequently connected to small cell lung cancer, while Option C (anti-LG1) is usually linked to autoimmune limbic encephalitis not typically related to testicular cancer. Option D is not provided. 1. In patients with known malignancy presenting with neurologic symptoms, always consider a paraneoplastic syndrome. 2. Anti-Ma2 is highly specific for testicular cancer\u2013related encephalitis. 3. Early detection and immunotherapy can improve patient outcomes by limiting neuronal injury. Recent studies underscore the importance of comprehensive antibody panels in diagnosing paraneoplastic syndromes. Updated guidelines advocate early immunomodulatory treatment coupled with aggressive oncologic management to optimize neurological outcomes.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of MS came with leg weakness started steroid improved, after one week, her symptoms came again in the same side, what is the next step.",
    "option_a": "Urinalysis",
    "option_b": "Pulse steroid",
    "option_c": "Change DMT",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is an autoimmune, demyelinating disease characterized by relapses and remissions. In some instances, new or recurrent symptoms may not represent new inflammatory activity but a pseudo-relapse triggered by infections or other systemic stressors. Infections, such as urinary tract infections, can lead to systemic inflammation and transiently worsen pre-existing neurological deficits without new demyelinating lesions. This pseudo-relapse phenomenon results from temporary conduction block in already compromised neural pathways rather than active plaque formation. A patient with MS who has shown improvement with steroids but then experiences a recurrence of symptoms should be evaluated for underlying triggers (e.g., infection). In this case, repeated leg weakness on the same side might indicate a pseudo-relapse rather than a new MS relapse, making it essential to rule out infections like a UTI. A detailed clinical history along with a thorough physical examination is essential. Urinalysis is a rapid, non-invasive screening tool to detect a urinary tract infection. Other assessments may include infection markers (e.g., CBC, CRP) and imaging if indicated. True relapses are generally confirmed by new lesions on MRI, whereas pseudo-relapses lack such findings. The initial step is to identify and treat any underlying infection (first-line use of diagnostic tests like urinalysis). If an infection is present, appropriate antimicrobial therapy is initiated. True relapses, in contrast, are managed with high-dose corticosteroids (pulse steroids) or other escalation in the disease-modifying therapy (DMT) regimen. In pregnant or lactating patients, careful assessment is required, and treatments such as steroids should be administered only after ruling out infections, given the potential risks to the fetus or infant. Option A (Urinalysis) is correct as it helps identify a common trigger for pseudo-relapse in MS, such as a UTI. Option B (Pulse steroid) would be appropriate for a true relapse but could be harmful if an infection is present. Option C (Change DMT) is a long-term management decision and is not indicated in the acute scenario of a potential infection-induced symptom recurrence. 1. Always rule out infections when an MS patient presents with recurrent or worsening symptoms following initial improvement. 2. Pseudo-relapses are common and can be triggered by factors like UTI or heat stress. 3. Differentiating between a pseudo-relapse and a true relapse is critical to avoid unnecessary escalation of immunosuppressive therapy. Current guidelines emphasize the importance of infection screening in MS patients presenting with new symptoms. Recent research has reinforced the concept of pseudo-relapse and its impact on clinical decision-making, advocating for a systematic approach to rule out confounders before initiating high-dose steroids.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of Miller Fisher what is the antibody:",
    "option_a": "GQ1b",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barr\u00e9 syndrome characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia. Its diagnosis is significantly aided by the detection of specific anti-ganglioside antibodies. The hallmark of MFS is the presence of anti-GQ1b antibodies, which are directed against gangliosides prevalent in the cranial nerves responsible for eye movements and proprioceptive neurons. These antibodies result from an aberrant immune response following a preceding infection, leading to demyelination or conduction block in these nerves. Patients typically present with acute onset ophthalmoplegia, loss of deep tendon reflexes, and ataxia. The identification of anti-GQ1b antibodies in the serum strongly supports the diagnosis, helping to distinguish MFS from other neurological disorders with similar presentations. Diagnosis is primarily clinical, with supportive evidence from cerebrospinal fluid (CSF) studies showing albuminocytologic dissociation and nerve conduction studies indicating demyelination. The detection of anti-GQ1b antibodies via serological testing is a key diagnostic step. Differential diagnoses include other subtypes of Guillain-Barr\u00e9 syndrome and cerebellar disorders. Management generally involves supportive care, with most patients showing spontaneous improvement. In severe or progressive cases, treatment with IV immunoglobulin (IVIG) or plasmapheresis may be considered. In pregnant or lactating patients who require immunotherapy, IVIG is regarded as safe and is the preferred treatment modality. Option A (GQ1b) is correct because anti-GQ1b antibodies are the most specific marker for Miller Fisher syndrome. The absence of additional options further supports the correctness of this choice. 1. MFS typically presents with a triad of ophthalmoplegia, ataxia, and areflexia. 2. Anti-GQ1b antibody testing is highly specific and crucial for diagnosis. 3. Most cases of MFS have a benign and self-limiting course. Recent literature reinforces the diagnostic value of anti-GQ1b antibodies in MFS. Current guidelines recommend supportive management with IVIG for severe cases, and emerging evidence continues to validate the safety of IVIG in pregnant and lactating patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A young man who had abdominal pain around 1 week back and had flu vaccine recently presented with 5 days history of progressive distal dysesthesias and facial hyperhidrosis later on he was tripping while walking and had weakness with decreased DTR on examination what is the diagnosis?",
    "option_a": "AIDP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common variant of Guillain-Barr\u00e9 syndrome (GBS). It is an immune-mediated neuropathy that typically follows an infectious trigger or, in rare cases, immunizations. AIDP results from an aberrant immune response, often triggered by a preceding gastrointestinal or respiratory infection or occasionally a vaccine. Molecular mimicry leads to an immune attack on peripheral nerve myelin, resulting in demyelination, slowed nerve conduction, and the clinical manifestations of weakness and sensory disturbances. The patient presents with progressive distal dysesthesias, weakness, and decreased deep tendon reflexes along with autonomic dysfunction (facial hyperhidrosis), which are typical of AIDP. The history of preceding abdominal pain and recent flu vaccination supports the diagnosis as these events are recognized triggers for GBS variants. Diagnosis is based on clinical evaluation supplemented by nerve conduction studies that demonstrate demyelination and cerebrospinal fluid (CSF) analysis that typically shows albuminocytologic dissociation. Differential diagnoses include chronic inflammatory demyelinating polyneuropathy (CIDP), metabolic neuropathies, and toxic neuropathies; these alternatives are differentiated based on the acute onset and characteristic laboratory findings in AIDP. First-line treatment for AIDP involves IV immunoglobulin (IVIG) or plasmapheresis. Supportive care, including close monitoring of respiratory function, is critical. Steroids are generally not effective in the treatment of AIDP. In pregnant or lactating patients, IVIG is preferred due to its favorable safety profile and minimal risk to the fetus or infant. Option A (AIDP) is correct because the clinical presentation\u2014progressive weakness, distal dysesthesias, decreased reflexes following a triggering event\u2014is consistent with the diagnosis of AIDP, the classic form of Guillain-Barr\u00e9 syndrome. Other options are not provided, consolidating AIDP as the most likely diagnosis. 1. Guillain-Barr\u00e9 syndrome can be triggered by both infections and, rarely, vaccines. 2. Early recognition of autonomic signs (such as facial hyperhidrosis) is crucial in managing potential complications. 3. Supportive care and prompt initiation of IVIG or plasmapheresis significantly improve outcomes. Recent guidelines continue to recommend IVIG or plasmapheresis as the cornerstones of therapy for AIDP. Ongoing research underscores the importance of early diagnosis and supportive management. Additionally, IVIG remains the treatment of choice in pregnant and lactating patients due to its established safety.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]